hme

Alison Birtle

United Kingdom
Alison Birtle
Alison Birtle

United Kingdom

Expert bio

Alison Birtle is a Consultant Clinical Oncologist and Honorary Senior Lecturer specialising in the treatment of urological cancers. She serves as an advisor on patient information for prostate, bladder, and testicular tumours for Macmillan Cancer Support (UK), as a Trustee and medical advisor for Fight Bladder cancer (UK), and as Secretary of the British Uro-oncology Group.

Dr Birtle completed her MD thesis on prostate specific antigen (PSA)-negative prostate cancers at the Institute of Urology, University College London, in London, UK.

She has previously been appointed as Clinical Cancer Research Lead for Lancashire and South Cumbria Cancer Research Network (UK), and since March 2018, Speciality Group Lead Cancer Research for the National Institute for Health Research (NIHR) Cancer Research Network North West Coast (CRN NWC).

Dr Birtle is a former member of the National Cancer Research Institute (NCRI) Prostate Clinical Study Group (CSG), served for two terms as Chair of the NIHR Bladder/Renal CSG, and remains a member of the Advanced Bladder Cancer Subgroup. Dr Birtle has been Principal Investigator and Chief Investigator on numerous urological clinical trials, and is the Chief Investigator on the POUT trial. She is passionate about patient access to clinical trials and believes in the mantra of “a trial for every patient”.

In 2018, Dr Birtle was named as one of “Health and Care’s Top 70 Stars”, an award presented by National Health Service (NHS) England and the NHS Confederations as part of the 70th anniversary of the NHS. She was also named CRN NWC Research Practitioner of the Year, in 2018, as well as runner-up in Lancashire Doctor of the Year. Dr Birtle has published widely and lectures nationally and internationally, and combines full-time NHS work with a passion for research, and for musical theatre.        

EM-10616- Date of preparation: May 2019

MORE INFORMATION
You can see my upcoming and previous webinars here.